Singular Genomics Announces Formation of Scientific Advisory Board

0
107

LA JOLLA, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the formation of its scientific advisory board (SAB). The SAB comprises a distinguished group of academic and industry experts who will advise on the company's product and service offerings and research and development pipeline.

“We are pleased to announce the launch of our scientific advisory board and are privileged to work with such accomplished leaders in science and medicine,” said Eli Glezer, Ph.D., Founder and Chief Scientific Officer of Singular Genomics and newly appointed Chair of the SAB. “This group's expertise in DNA sequencing, human genetics, oncology and immunology will be an invaluable resource as we expand the applications of our G4 sequencing system and develop the PX platform as a powerful tool for spatial biology.”

The members of Singular's SAB include:

  • David L. Barker, Ph.D., Board Member of Singular Genomics, AmideBio, and Aspen Neuroscience, Scientific Advisor to Luna DNA, and Board Member and Chairman at Bionano Genomics. Dr. Barker previously served as Vice President and Chief Scientific Officer of Illumina, while also sitting on their Scientific Advisory Board. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a Postdoctoral Fellow at Harvard Medical School, Assistant Professor at the University of Oregon, and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a Ph.D. in Biochemistry from Brandeis University.
  • Lawrence Fong, M.D., Efim Guzik Distinguished Professor in Cancer Biology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF); Co-Director of the Parker Institute of Cancer Immunotherapy at UCSF; Co-Lead of the Cancer Immunity and Immunotherapy Program in the UCSF Cancer Center. Dr. Fong is also a physician-scientist in the Department of Medicine, Division of Hematology/Oncology at UCSF, where he directs both a translational research program and an NIH-funded research lab. Dr. Fong's research examines the …

Full story available on Benzinga.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here